Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$17.14 +0.4%	$13.15	$7.75 ▼ $19.93	$130.45M	0.55	26,240 shs	18,229 shs
GALT Galectin Therapeutics	$3.29 +37.7%	$1.39	$0.73 ▼ $3.30	$151.27M	0.54	388,765 shs	5.37 million shs
NKTX Nkarta	$1.82 +0.6%	$1.87	$1.31 ▼ $8.23	$128.43M	0.72	1.06 million shs	430,106 shs
VTL Vital Therapies	$0.75 -2.7%	$8.88	$0.15 ▼ $9.75	$31.63M	3.51	21.62 million shs	1.20 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+0.35%	+0.53%	+24.20%	+60.34%	+15.19%
GALT Galectin Therapeutics	+37.66%	+149.24%	+147.37%	+115.03%	+41.20%
NKTX Nkarta	+0.55%	-9.00%	+7.06%	+21.33%	-65.46%
VTL Vital Therapies	-6.46%	-13.31%	-20.14%	-33.84%	-32.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	4.0202 of 5 stars	3.3	5.0	0.0	4.7	1.4	0.8	0.0
GALT Galectin Therapeutics	1.4251 of 5 stars	3.5	0.0	0.0	0.0	2.0	1.7	0.0
NKTX Nkarta	3.4298 of 5 stars	4.6	3.0	0.0	0.0	2.0	1.7	0.6
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.67	Moderate Buy	$33.00	92.53% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	82.37% Upside
NKTX Nkarta	3.13	Buy	$14.33	687.55% Upside
VTL Vital Therapies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VTL, NKTX, ASMB, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/27/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
3/27/2025	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/25/2025	ASMB Assembly Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
3/24/2025	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$28.52M	4.59	N/A	N/A	$5.25 per share	3.26
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	$0.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$40.18M	-$6.23	N/A	N/A	N/A	-124.15%	-131.77%	-36.81%	8/6/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/11/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
VTL Vital Therapies	-$41.47M	N/A	0.00	∞	N/A	N/A	-235.33%	-182.35%	N/A

Latest VTL, NKTX, ASMB, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/8/2025	Q1 2025	ASMB Assembly Biosciences	-$2.01	-$1.17	+$0.84	-$1.17	$7.41 million	$9.42 million
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/20/2025	Q4 2024	ASMB Assembly Biosciences	-$1.75	-$1.57	+$0.18	-$1.57	$7.05 million	$7.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	2.05	2.05
GALT Galectin Therapeutics	N/A	0.08	0.08
NKTX Nkarta	N/A	14.48	14.48
VTL Vital Therapies	N/A	6.97	6.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
GALT Galectin Therapeutics	11.68%
NKTX Nkarta	80.54%
VTL Vital Therapies	15.52%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.30%
GALT Galectin Therapeutics	50.10%
NKTX Nkarta	8.40%
VTL Vital Therapies	33.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.64 million	7.23 million	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
VTL Vital Therapies	10	42.37 million	N/A	Not Optionable

VTL, NKTX, ASMB, and GALT Headlines

Recent News About These Companies

18,000 vulnerable children could lose ‘vital’ therapy as adoption fund faces axe

March 31, 2025 | msn.com

Veterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And Healing

November 11, 2024 | benzinga.com

Respiratory Therapy program continues to thrive at Vermont State University

November 6, 2024 | vermontbiz.com

Respiratory Therapy program continues to thrive at Vermont State University

November 6, 2024 | vermontbiz.com

Lighthouse Center for Vital Living celebrates new building

October 30, 2024 | duluthnewstribune.com

Alternative Wellness Therapies in the Tahoe Basin

October 11, 2024 | tahoedailytribune.com

Addressing Trauma: A Vital Component in Behavioral Health

October 3, 2024 | ajmc.com

Vital Care Receives Strategic Investment From Berkshire Partners, Leonard Green & Partners, and Linden Capital Partners

August 1, 2024 | tmcnet.com

Veterans lobbied for psychedelic therapy, but it may not be enough to save MDMA drug application

July 26, 2024 | msn.com

Ending Therapy

May 24, 2024 | psychologytoday.com

Medication and Therapy

May 23, 2024 | psychologytoday.com

Vardhman Textiles Ltd.

May 22, 2024 | wsj.com

FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversight

May 11, 2024 | biospace.com

Vital Spa celebrates a year on Bridge Street

April 28, 2024 | yahoo.com

Guest opinion: Psychedelics as a vital path to healing for veterans

April 28, 2024 | heraldextra.com

Don’t Forget About Vital Signs in Psychiatry Visits

March 12, 2024 | psychologytoday.com

What is therapeutic recreation? Champaign counselors train to include it in their sessions

March 8, 2024 | yahoo.com

Teen Therapy and Psychiatry Online: Hit or Miss?

March 3, 2024 | medpagetoday.com

Vital Ltd VTL

March 2, 2024 | morningstar.com

The Benefits of Teen Outpatient Programs for Behavioral Health

March 2, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTL, NKTX, ASMB, and GALT Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$17.14 +0.06 (+0.35%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$17.18 +0.04 (+0.20%)

As of 06/18/2025 04:04 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Galectin Therapeutics NASDAQ:GALT

$3.29 +0.90 (+37.66%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.29 0.00 (0.00%)

As of 06/18/2025 07:59 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Nkarta NASDAQ:NKTX

$1.82 +0.01 (+0.55%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.83 +0.01 (+0.77%)

As of 06/18/2025 05:09 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Vital Therapies NASDAQ:VTL

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time